Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Section 6 of 6

References

161 sources

  1. Adstiladrin prescribing information (2026) (opens in a new tab)
  2. American Cancer Society Cancer Facts and Figures (2026) (opens in a new tab)
  3. Anktiva prescribing information (2026) (opens in a new tab)
  4. Balar et al. (2021) (opens in a new tab)
  5. Beinfeld et al. (2021) (opens in a new tab)
  6. Bhanvadia et al. (2021) (opens in a new tab)
  7. Bivalacqua (2025) (opens in a new tab)
  8. Bivalacqua et al. (2026) (opens in a new tab)
  9. Boorjian et al. (2021) (opens in a new tab)
  10. Burke et al. (2010) (opens in a new tab)
  11. Burke et al. (2012) (opens in a new tab)
  12. CG Oncology BOND-003 24-month data press release (2025) (opens in a new tab)
  13. CG Oncology CORE-001 final results press release (2024) (opens in a new tab)
  14. CG Oncology CORE-001 Nature Medicine publication press release (2024) (opens in a new tab)
  15. CG Oncology CORE-001 protocol (2024) (opens in a new tab)
  16. CG Oncology expanded access program press release (2024) (opens in a new tab)
  17. CG Oncology Fast Track and Breakthrough Therapy press release (2023) (opens in a new tab)
  18. CG Oncology first-quarter 2026 results press release (2026) (opens in a new tab)
  19. CG Oncology Form 10-K (2026) (opens in a new tab)
  20. CG Oncology Form 10-Q (2026) (opens in a new tab)
  21. CG Oncology investor presentation (2026) (opens in a new tab)
  22. CG Oncology Lancet Oncology publication press release (2026) (opens in a new tab)
  23. CG Oncology PIVOT-006 topline press release (2026) (opens in a new tab)
  24. CG Oncology prospectus (2024) (opens in a new tab)
  25. CG Oncology SUO 2025 data press release (2025) (opens in a new tab)
  26. CG Oncology third-quarter 2025 results press release (2025) (opens in a new tab)
  27. CG Oncology third-quarter 2026 results press release (2026) (opens in a new tab)
  28. Chamie et al. (2013) (opens in a new tab)
  29. Chamie et al. (2024) (opens in a new tab)
  30. Chandra et al. (2023) (opens in a new tab)
  31. Chang et al. (2026a) (opens in a new tab)
  32. Chang et al. (2026b) (opens in a new tab)
  33. Chevuru et al. (2023) (opens in a new tab)
  34. Chun et al. (2023) (opens in a new tab)
  35. ClinicalTrials.gov NCT00109655 (opens in a new tab)
  36. ClinicalTrials.gov NCT01438112 (opens in a new tab)
  37. ClinicalTrials.gov NCT02365818 (opens in a new tab)
  38. ClinicalTrials.gov NCT04387461 (opens in a new tab)
  39. ClinicalTrials.gov NCT04452591 (opens in a new tab)
  40. ClinicalTrials.gov NCT04752722 (opens in a new tab)
  41. ClinicalTrials.gov NCT06211764 (opens in a new tab)
  42. ClinicalTrials.gov NCT06443944 (opens in a new tab)
  43. ClinicalTrials.gov NCT07283835 (opens in a new tab)
  44. Clinton et al. (2026a) (opens in a new tab)
  45. Clinton et al. (2026b) (opens in a new tab)
  46. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  47. CMS Physician Fee Schedule Relative Value File (2026) (opens in a new tab)
  48. Cohen (2026) (opens in a new tab)
  49. Colbert et al. (2025) (opens in a new tab)
  50. Cooper et al. (2023) (opens in a new tab)
  51. D'Andrea et al. (2025) (opens in a new tab)
  52. Daneshmand et al. (2025) (opens in a new tab)
  53. de Jong et al. (2023) (opens in a new tab)
  54. Dinney (2026c) (opens in a new tab)
  55. Dinney et al. (2026a) (opens in a new tab)
  56. Dinney et al. (2026b) (opens in a new tab)
  57. Donahue et al. (2025) (opens in a new tab)
  58. eCQI CMS646v6 Intravesical BCG for NMIBC (2026) (opens in a new tab)
  59. enGene LEGEND Cohort 1 and BLA plan press release (2026) (opens in a new tab)
  60. European Association of Urology NMIBC Guidelines (2026) (opens in a new tab)
  61. Faraj et al. (2020) (opens in a new tab)
  62. Farré et al. (2025) (opens in a new tab)
  63. FDA BCG-unresponsive NMIBC draft guidance (2024) (opens in a new tab)
  64. FDA BCG-unresponsive NMIBC guidance (2018) (opens in a new tab)
  65. FDA nogapendekin alfa inbakicept-pmln expanded indication notice (2026) (opens in a new tab)
  66. Ferring Adstiladrin Connecticut WAC disclosure (2026) (opens in a new tab)
  67. Giatsoglou et al. (2026) (opens in a new tab)
  68. Gore et al. (2026) (opens in a new tab)
  69. Griebsch et al. (2025) (opens in a new tab)
  70. Haas et al. (2016) (opens in a new tab)
  71. Heiss et al. (2025) (opens in a new tab)
  72. Herr et al. (2015) (opens in a new tab)
  73. ICER Bladder Cancer Final Evidence Report (2020) (opens in a new tab)
  74. ImmunityBio Anktiva Colorado WAC disclosure (2025) (opens in a new tab)
  75. ImmunityBio ISPOR 2026 health economic analysis press release (2026) (opens in a new tab)
  76. Inlexzo prescribing information (2025) (opens in a new tab)
  77. Jazayeri et al. (2026) (opens in a new tab)
  78. Joshi et al. (2023) (opens in a new tab)
  79. Jung et al. (2019) (opens in a new tab)
  80. Kamat et al. (2016) (opens in a new tab)
  81. Kamat et al. (2023) (opens in a new tab)
  82. Kassouf et al. (2026) (opens in a new tab)
  83. Kates et al. (2020) (opens in a new tab)
  84. Kissei Pharmaceutical Lancet Oncology publication press release (2026) (opens in a new tab)
  85. Kurnot and Kaye (2024) (opens in a new tab)
  86. Lenis et al. (2020) (opens in a new tab)
  87. Lerner et al. (2015) (opens in a new tab)
  88. Li et al. (2021) (opens in a new tab)
  89. Li et al. (2023) (opens in a new tab)
  90. Li et al. (2024a) (opens in a new tab)
  91. Li et al. (2024b) (opens in a new tab)
  92. Lindskrog et al. (2021) (opens in a new tab)
  93. Lotan et al. (2025) (opens in a new tab)
  94. Mariotto et al. (2020) (opens in a new tab)
  95. Marqueen et al. (2018) (opens in a new tab)
  96. Mauskopf et al. (2007) (opens in a new tab)
  97. Merck KEYTRUDA cost information (2026) (opens in a new tab)
  98. Merck KEYTRUDA prescribing information (2026) (opens in a new tab)
  99. Merck TICE BCG HCP letter (2026) (opens in a new tab)
  100. MHLW orphan regenerative medical product designation (2025) (opens in a new tab)
  101. Miyake et al. (2026) (opens in a new tab)
  102. Mohamed et al. (2021) (opens in a new tab)
  103. Mokkapati (2025) (opens in a new tab)
  104. Mossanen et al. (2019) (opens in a new tab)
  105. Moyer et al. (2026a) (opens in a new tab)
  106. Moyer et al. (2026b) (opens in a new tab)
  107. Myers et al. (2024) (opens in a new tab)
  108. Myers et al. (2026) (opens in a new tab)
  109. Nadelmann et al. (2026) (opens in a new tab)
  110. Narayan et al. (2024) (opens in a new tab)
  111. National Cancer Institute PDQ Bladder Cancer Treatment (2025) (opens in a new tab)
  112. Nature Medicine CORE-001 article Table 1 (2024) (opens in a new tab)
  113. Nature Medicine CORE-001 article Table 2 (2024) (opens in a new tab)
  114. Nature Medicine CORE-001 author correction (2024) (opens in a new tab)
  115. Nature Medicine CORE-001 publisher correction (2024) (opens in a new tab)
  116. Nayak et al. (2021) (opens in a new tab)
  117. Necchi et al. (2024) (opens in a new tab)
  118. Nemunaitis et al. (2008) (opens in a new tab)
  119. Packiam et al. (2018) (opens in a new tab)
  120. Pinton et al. (2026) (opens in a new tab)
  121. Presicce et al. (2021) (opens in a new tab)
  122. Preston (2026) (opens in a new tab)
  123. Raj et al. (2007) (opens in a new tab)
  124. Rieger et al. (2024) (opens in a new tab)
  125. Robesti et al. (2026) (opens in a new tab)
  126. Scilipoti et al. (2025) (opens in a new tab)
  127. SEER Cancer Stat Facts Bladder Cancer (2026) (opens in a new tab)
  128. Senzer et al. (2006) (opens in a new tab)
  129. Shabsigh et al. (2009) (opens in a new tab)
  130. Shimko et al. (2011) (opens in a new tab)
  131. Smith et al. (2026) (opens in a new tab)
  132. Steinberg et al. (2016) (opens in a new tab)
  133. Steinberg et al. (2020) (opens in a new tab)
  134. Steinberg et al. (2026) (opens in a new tab)
  135. Su et al. (2025) (opens in a new tab)
  136. Sullivan et al. (2014) (opens in a new tab)
  137. Svatek et al. (2014) (opens in a new tab)
  138. Sylvester et al. (2006) (opens in a new tab)
  139. Sylvester et al. (2021) (opens in a new tab)
  140. Tan et al. (2023) (opens in a new tab)
  141. Tan et al. (2026) (opens in a new tab)
  142. Taylor et al. (2025a) (opens in a new tab)
  143. Taylor et al. (2025b) (opens in a new tab)
  144. Tyson (2025a) (opens in a new tab)
  145. Tyson (2025b) (opens in a new tab)
  146. Tyson (2025e) (opens in a new tab)
  147. Tyson et al. (2025c) (opens in a new tab)
  148. Tyson et al. (2025d) (opens in a new tab)
  149. Tyson et al. (2026) (opens in a new tab)
  150. Uchio et al. (2020) (opens in a new tab)
  151. Uchio et al. (2021) (opens in a new tab)
  152. Valstar prescribing information (2016) (opens in a new tab)
  153. WHO proposed INN List 127 (2022) (opens in a new tab)
  154. WHO recommended INN List 89 (2023) (opens in a new tab)
  155. Williams et al. (2021) (opens in a new tab)
  156. Williams et al. (2025) (opens in a new tab)
  157. Williams et al. (2026) (opens in a new tab)
  158. Wymer et al. (2021) (opens in a new tab)
  159. Yang et al. (2021) (opens in a new tab)
  160. Yang et al. (2026) (opens in a new tab)
  161. Zhang and Qi (2024) (opens in a new tab)